Access to drugs

chemotherapy drugs used for pancreatic cancerWe believe that patients, no matter where they live should have access to drugs that treat pancreatic cancer which have been approved by regulatory bodies such as the European Medicines Agency (EMA).

Pancreatic cancer survival rates have not changed in nearly five decades and, aside from late diagnosis, much of this can be attributed to the lack of treatment options for patients.

In 2013, a new drug was newly licensed for pancreatic cancer. It was the first to offer a significant survival advantage in nearly 18 years. However, the NHS in England has decided not to fund it on grounds of cost. Patients in Wales and Scotland are able to routinely access it on the NHS.

We are concerned that there is huge variation in the ability of patients across the UK to access any new drugs to show promise for the disease, resulting in inequality in treatment which in turn could lead to inequalities in survival across the UK. This is unacceptable and unfair.

Cannula for chemotherapyWhat do we need to see?

We believe there should be a drug appraisal system in the UK that, where drugs that are innovative and where clinical benefit is demonstrated, should consider pancreatic cancer as a disease of unmet need and apply more flexible criteria to their cost-benefit analyses so drugs can be approved for routine use by patients on the NHS. Currently, the one-size–fits-all approach is preventing these innovative treatments from reaching patients in certain parts of the UK.

We believe that:

Abraxane petition London Nov 2015How we campaign for fair access to latest treatments:

How you can help